Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion

By Associated Press - Thursday, January 3, 2019

NEW YORK (AP) - Bristol-Myers Squibb to buy Celgene in a cash and stock deal worth $74 billion.

Bible prophecy fulfilled? What pastors, theologians say about the birth of Christ